- Home
- NAPA vs ELVN Comparison
NAPA vs ELVN Comparison
Compare NAPA & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NAPA
- ELVN
- Stock Information
- Founded
- NAPA 1976
- ELVN 2016
- Country
- NAPA United States
- ELVN United States
- Employees
- NAPA N/A
- ELVN N/A
- Industry
- NAPA Beverages (Production/Distribution)
- ELVN Biotechnology: Pharmaceutical Preparations
- Sector
- NAPA Consumer Staples
- ELVN Health Care
- Exchange
- NAPA Nasdaq
- ELVN Nasdaq
- Market Cap
- NAPA 1.6B
- ELVN 1.3B
- IPO Year
- NAPA 2021
- ELVN 2020
- Fundamental
- Price
- NAPA $11.01
- ELVN $24.41
- Analyst Decision
- NAPA Buy
- ELVN Strong Buy
- Analyst Count
- NAPA 8
- ELVN 4
- Target Price
- NAPA $10.76
- ELVN $36.75
- AVG Volume (30 Days)
- NAPA 1.3M
- ELVN 243.2K
- Earning Date
- NAPA 12-04-2024
- ELVN 11-13-2024
- Dividend Yield
- NAPA N/A
- ELVN N/A
- EPS Growth
- NAPA N/A
- ELVN N/A
- EPS
- NAPA 0.45
- ELVN N/A
- Revenue
- NAPA $405,481,000.00
- ELVN N/A
- Revenue This Year
- NAPA $22.74
- ELVN N/A
- Revenue Next Year
- NAPA $6.79
- ELVN N/A
- P/E Ratio
- NAPA $24.49
- ELVN N/A
- Revenue Growth
- NAPA 0.62
- ELVN N/A
- 52 Week Low
- NAPA $5.38
- ELVN $9.80
- 52 Week High
- NAPA $11.07
- ELVN $30.03
- Technical
- Relative Strength Index (RSI)
- NAPA 79.44
- ELVN 30.68
- Support Level
- NAPA $10.94
- ELVN $27.02
- Resistance Level
- NAPA $11.07
- ELVN $29.79
- Average True Range (ATR)
- NAPA 0.04
- ELVN 1.37
- MACD
- NAPA -0.16
- ELVN -0.60
- Stochastic Oscillator
- NAPA 45.45
- ELVN 11.67
About NAPA The Duckhorn Portfolio Inc.
The Duckhorn Portfolio Inc produces luxury and ultra-luxury wine across a portfolio of winery brands, including Duckhorn Vineyards, Paraduxx, Goldeneye, Migration, Decoy, Canvasback, Calera, Kosta Browne, Greenwing and Postmark. Its revenue is comprised of wholesale and direct-to-consumer sales. Wholesale revenue is generated through sales directly to California retailers and restaurants, sales to distributors and agents located in other states throughout the United States, and sales to export distributors that sell internationally.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.